These findings are consistent with the mode of action of Codrituzumab, which requires engagement of the CD16/FcγRIIIa receptor in NK cells to recruit NK cells to the tumor with subsequent tumor lysis [5]. This evidence concerns the gene FCGR3A and neoplasm.